nacubactam   Click here for help

GtoPdb Ligand ID: 10833

Synonyms: OP-0595 | OP0595 | RG-6080 | RG6080 | RO-7079901 | RO7079901
Compound class: Synthetic organic
Comment: Nacubactam is a β-lactamase inhibitor [1], intended for use alongside β-lactamase-sensitive antibacterials [2-3].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 159.88
Molecular weight 324.07
XLogP -3.31
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
Isomeric SMILES NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
InChI InChI=1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)/t6-,7+/m1/s1
InChI Key RSBPYSTVZQAADE-RQJHMYQMSA-N
References
1. Kaushik A, Ammerman NC, Parrish NM, Nuermberger EL. (2019)
New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.
Antimicrob Agents Chemother, 63 (9). DOI: 10.1128/AAC.00733-19 [PMID:31209013]
2. Monogue ML, Giovagnoli S, Bissantz C, Zampaloni C, Nicolau DP. (2018)
In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.
Antimicrob Agents Chemother, 62 (9). [PMID:30012751]
3. Mushtaq S, Vickers A, Woodford N, Haldimann A, Livermore DM. (2019)
Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae.
J Antimicrob Chemother, 74 (4): 953-960. [PMID:30590470]